Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.
Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML
Recent Articles
$3.5 Trillion Proposal by Senate Democrats Includes Drug Pricing Provisions to Offset Spending
A $3.5 trillion draft package framework recently proposed by Senate Democrats includes several drug pricing provisions intended to help offset the costs of initiatives...
FDA Committee Votes Against Approval of Roxadustat for Anemia of Chronic Kidney Disease
The U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has decided not to recommend the approval of roxadustat for...
What Will Telehealth Look Like Post-Pandemic?
As emergency orders easing restrictions on telehealth during the COVID-19 pandemic are lifted, patients and physicians are struggling to keep up with rapidly changing...
Pain, Comorbidities Increase Risk of Severe COVID-19 in Patients with SCD
Research published in Blood Advances found patients with sickle cell disease (SCD) and a history of pain and renal and heart/lung comorbidities have a...
Current Issue
July 2021 Bonus Mid-Year Edition, Volume 7 Issue 9
This issue features conversations with ASH Clinical Research Training Institute graduates, highlights from the virtual ASCO and EHA annual meetings, and more.